ADR: the number of shares per ADR isn’t known yetADR: the number of shares per ADR isn’t known yet, so we show no figure rather than a guess. Shares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily.CIK 1479615The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
—
No open-market trades
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Silence Therapeutics Plc's latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Silence Therapeutics Plc and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
40
17 added · 10 trimmed
Latest 10-Q
Q3 2026
What changed in Silence Therapeutics Plc's latest quarterly report, compared with the one before.
Filed Nov 13, 2026 · Quarter ended Sep 30, 2026
Summary text goes here once it has loaded. Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
AI summary of changes vs the prior report. Written by AI from the paragraphs that changed, and checked against them. This is information, not investment advice.
Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
No recent insider purchases or sales for this company.
13F holders
16.51M shares
40 funds report SLN. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Q3 2026. 10 new, 17 added to, 10 trimmed, 41 exited since Q2 2026.
Download CSVEvery fund that holds SLN, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
No recent congressional trades for this company.
Lobbying
What Silence Therapeutics Plc and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q3 2020
2
—
542,000
$8.1M
Q4 2020
3
+1
542,093
$10.2M
Q1 2021
6
+3
2.55M
$55.9M
Q2 2021
6
0
2.26M
$56.4M
Q3 2021
7
+1
1.96M
$39.4M
Q4 2021
22
+15
10.34M
$246.6M
Q1 2022
26
+4
12.84M
$230.8M
Q2 2022
25
-1
11.01M
$124.0M
Q3 2022
29
+4
19.30M
$189.8M
Q4 2022
27
-2
18.64M
$275.7M
Q1 2023
29
+2
18.40M
$110.2M
Q2 2023
29
0
19.23M
$101.8M
Q3 2023
28
-1
19.72M
$187.6M
Q4 2023
34
+6
20.60M
$345.0M
Q1 2024
64
+30
28.22M
$598.7M
Q2 2024
71
+7
28.91M
$534.1M
Q3 2024
69
-2
28.20M
$493.1M
Q4 2024
65
-4
24.82M
$168.2M
Q1 2025
59
-6
21.92M
$60.6M
Q2 2025
55
-4
19.76M
$108.1M
Q3 2025
54
-1
19.71M
$96.5M
Q4 2025
58
+4
18.26M
$107.1M
Q1 2026
56
-2
19.91M
$102.1M
Q2 2026
72
+16
23.58M
$253.5M
Q3 2026
40
-32
16.51M
$172.6M
Each point is a quarter-end, from Q3 2020 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (82686Q101). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2020) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.